Other
Gain (loss) recognized in income on derivatives
West Pharmaceutical Services Gain (loss) recognized in income on derivatives increased by 1050.0% to $1.9M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1050.0%, from -$200K to $1.9M.
Analysis
StatementCash Flow Statement
SectionOther
First reportedQ1 2022
Last reportedQ1 2026Apr 23, 2026
Metric ID:
other_derivative_instruments_not_designated_as_hedging_i_03b97dHistorical Data
8 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $2.8M | $300K | -$1.5M | -$600K | -$400K | $500K | -$200K | $1.9M |
| QoQ Change | — | -89.3% | -600.0% | +60.0% | +33.3% | +225.0% | -140.0% | >999% |
| YoY Change | — | — | — | -121.4% | -233.3% | +133.3% | — | >999% |
Range-$1.5M – $2.8M
CAGR-19.9%
Avg YoY Growth+207.1%
Median YoY Growth+6.0%
Gain (loss) recognized in income on derivatives at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's gain (loss) recognized in income on derivatives?
- West Pharmaceutical Services (WST) reported gain (loss) recognized in income on derivatives of $1.9M in Q1 2026.
- How has West Pharmaceutical Services's gain (loss) recognized in income on derivatives changed year-over-year?
- West Pharmaceutical Services's gain (loss) recognized in income on derivatives increased by 1050.0% year-over-year, from -$200K to $1.9M.